Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer

As the predominant treatment option of the immunotherapy for advanced esophageal cancer (EC), the application of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors brings new hope to clinical practice. However, a considerable portion of patients do not response to this therap...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Chao Cheng, Lingdun Zhuge, Xin Xiao, Siyuan Luan, Yong Yuan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Subjects:	esophageal cancer immunotherapy resistance immune checkpoint inhibitors programmed death 1 programmed death-ligand 1
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.955163/full